D-0110-2027 Class II Ongoing
FDA drug recall D-0110-2027 was initiated by Brandywine Pharmaceuticals, LLC on Oct 6, 2026 and is designated Class II. Reason for recall: CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory The recall status is ongoing. Affected quantity: 1,620 100-count bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 4, 2026
- Initiation Date
- Oct 6, 2026
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 1,620 100-count bottles
Product description
Theophylline Extended-Release Tablets, 100 mg, Rx Only, 100-count bottle, Distributed by: Brandywine Pharmaceuticals, LLC, West Chester, PA 19382, NDC: 71321-500-10
Reason for recall
CGMP Deviations: interruption in the ongoing stability testing program conducted at a third-party laboratory
Distribution pattern
Nationwide within U.S
Code information
Lot: 405617, Expiry: 03/31/2028
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0110-2027
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026